1-(tert-butoxymethyl)piperidine | 1628470-82-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(tert-butoxymethyl)piperidine
• 英文别名: 1-[(2-Methylpropan-2-yl)oxymethyl]piperidine
• CAS: 1628470-82-5
• 化学式: C₁₀H₂₁NO
• 分子量: 171.283
• InChiKey: YJLRJKLBCPWOSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(tert-butoxymethyl)piperidine 、 dimethyl(2-(4-chlorophenyl)ethynyl)aluminum 以 甲苯 为溶剂， 反应 0.5h， 以97%的产率得到1-(3-(4-chlorophenyl)prop-2-ynyl)piperidine
  参考文献：
  名称：

  通过在N，N-双取代的甲酰胺和N，O-缩醛中添加炔基二甲基铝试剂合成N，N-二取代的3-氨基-1,4-二炔和3-氨基-1-炔

  摘要：

  将一系列炔基二甲基铝试剂添加到N，N-二取代的甲酰胺及其缩醛中，以提供相应的N，N-二取代的3-氨基-1,4-二炔。同样，这些试剂平稳地添加到N，O-乙缩醛中，得到相应的N，N-二取代的3-amino-1-ynes。

  DOI：

  10.1002/ejoc.201402464

文献信息

• Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same
  申请人：Miwa Atsushi

  公开号：US20080207617A1

  公开（公告）日：2008-08-28

  An objective of the present invention is to provide compounds and pharmaceuticals useful for the treatment of disease where the inhibition of autophosphorylation of FMS-like tyrosine kinase 3(Flt3) is therapeutically effective. The present invention relates to a pharmaceutical composition for use in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3 therapeutically or prophylactically effective, which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; R 1 , R 2 , and R 3 represent H, OH, or optionally substituted alkoxy; R 4 represents H; R 5 , R 6 , R 7 , and R 8 represent H, Hal, alkyl or the like; and R 9 represents, e.g., alkyl substituted by t-butyl or the like.

  本发明的目标是提供化合物和药物，用于治疗抑制FMS样酪氨酸激酶3（Flt3）自磷酸化在治疗上具有疗效的疾病。本发明涉及一种药物组合物，用于治疗或预防抑制Flt3自磷酸化在治疗或预防上具有疗效的疾病，所述药物组合物包括以下公式（I）所表示的化合物或其药学上可接受的盐或溶剂：其中X代表CH或N；Z代表O或S；R1、R2和R3代表H、OH或可选取代的烷氧基；R4代表H；R5、R6、R7和R8代表H、卤素、烷基或类似物；R9代表例如被t-丁基或类似物取代的烷基。
• Pyrrolotriazine Derivatives Useful For Treating Hyper-Proliferative Disorders And Diseases Associated With Angiogenesis
  申请人：Dixon A. Julie

  公开号：US20070208013A1

  公开（公告）日：2007-09-06

  This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.

  本发明涉及新型吡唑三嗪化合物，含有这些化合物的药物组合物以及将这些化合物和组合物用于预防和/或治疗与血管生成相关的过度增殖性疾病的用途。
• PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
  申请人：Dixon Julie A.

  公开号：US20100075958A1

  公开（公告）日：2010-03-25

  This invention relates to pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.

  本发明涉及吡咯烷三嗪化合物，含有这种化合物的制药组合物以及这些化合物和组合物在预防和/或治疗与血管生成相关的高增殖性疾病和疾病方面的使用。
• FACTOR XA INHIBITORS
  申请人：Zhu Bing-Yan

  公开号：US20120178733A1

  公开（公告）日：2012-07-12

  The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

  本发明涉及由I式表示的化合物及其药学上可接受的盐、溶剂、水合物和前药，这些化合物是Xa因子的抑制剂。本发明还涉及用于制备这些化合物的中间体，含有这些化合物的药物组合物，预防或治疗由不良血栓形成引起的多种情况的方法，以及抑制血样的凝血方法。
• TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS
  申请人：Coghlan Michael Joseph

  公开号：US20090149445A1

  公开（公告）日：2009-06-11

  The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.

  本发明涉及治疗容易受到类固醇激素核受体调节的病理性疾病的方法，包括向需要治疗的患者施用化合物的有效量，该化合物的公式为：或其药学上可接受的盐。此外，本发明提供了公式I的新型药物化合物，包括其药学上可接受的盐，以及含有公式I化合物作为活性成分的药物组合物。